1. Home
  2. VIVS

as 06-06-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 3.6M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 71.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.70 EPS Growth: N/A
52 Week Low/High: $1.56 - $21.96 Next Earning Date: 06-13-2025
Revenue: $144,000 Revenue Growth: -49.59%
Revenue Growth (this year): 59.08% Revenue Growth (next year): 18.24%

Share on Social Networks: